<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Equillium Inc — News on 6ix</title>
<link>https://6ix.com/company/equillium-inc</link>
<description>Latest news and press releases for Equillium Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 20 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/equillium-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683563cf78dffbe2df0ef67d.webp</url>
<title>Equillium Inc</title>
<link>https://6ix.com/company/equillium-inc</link>
</image>
<item>
<title>Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event</title>
<link>https://6ix.com/company/equillium-inc/news/equillium-to-participate-in-oppenheimers-2026-innovation-on-the-island-event</link>
<guid isPermaLink="true">https://6ix.com/company/equillium-inc/news/equillium-to-participate-in-oppenheimers-2026-innovation-on-the-island-event</guid>
<pubDate>Mon, 20 Apr 2026 20:05:00 GMT</pubDate>
<description>LA JOLLA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will be presenting at Oppenheimer’s 2026 Innovation on the Island Event on Tuesday April 28, 2026 at 7:50am AST. Members of the Equillium management team will be available to meet with investors who are registered to attend the conference. About EquilliumEquillium is a biotech</description>
</item>
<item>
<title>Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists</title>
<link>https://6ix.com/company/equillium-inc/news/equillium-announces-poster-presentations-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists</link>
<guid isPermaLink="true">https://6ix.com/company/equillium-inc/news/equillium-announces-poster-presentations-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>LA JOLLA, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe</description>
</item>
<item>
<title>Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights</title>
<link>https://6ix.com/company/equillium-inc/news/equillium-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-and-clinical-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/equillium-inc/news/equillium-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-and-clinical-highlights</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months thereafter Cash and cash</description>
</item>
<item>
<title>Equillium to Participate in the 38th Annual Roth Conference</title>
<link>https://6ix.com/company/equillium-inc/news/equillium-to-participate-in-the-38th-annual-roth-conference</link>
<guid isPermaLink="true">https://6ix.com/company/equillium-inc/news/equillium-to-participate-in-the-38th-annual-roth-conference</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>LA JOLLA, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe</description>
</item>
<item>
<title>Equillium Announces $35 Million Financing with RA Capital Management</title>
<link>https://6ix.com/company/equillium-inc/news/equillium-announces-dollar35-million-financing-with-ra-capital-management-106</link>
<guid isPermaLink="true">https://6ix.com/company/equillium-inc/news/equillium-announces-dollar35-million-financing-with-ra-capital-management-106</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Capital strengthens the advancement of EQ504 through key clinical milestones Anticipated net proceeds, along with existing cash and cash equivalents, expected</description>
</item>
<item>
<title>Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference</title>
<link>https://6ix.com/company/equillium-inc/news/equillium-to-participate-in-the-leerink-partners-2026-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/equillium-inc/news/equillium-to-participate-in-the-leerink-partners-2026-global-healthcare-conference</guid>
<pubDate>Wed, 25 Feb 2026 13:30:00 GMT</pubDate>
<description>LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026 at 10:40am ET. Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the confer</description>
</item>
<item>
<title>Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/equillium-inc/news/equillium-reports-inducement-grants-under-210500837</link>
<guid isPermaLink="true">https://6ix.com/company/equillium-inc/news/equillium-reports-inducement-grants-under-210500837</guid>
<pubDate>Mon, 02 Feb 2026 21:05:00 GMT</pubDate>
<description>LA JOLLA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on January 30, 2026, the Compensation Committee of Equillium’s Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase an aggregate of 59,750 shares of common stock to two new employees under Equillium’s 2024 Inducement Plan. The Compensation Comm</description>
</item>
<item>
<title>Equillium to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/equillium-inc/news/equillium-participate-upcoming-investor-conferences-213500234</link>
<guid isPermaLink="true">https://6ix.com/company/equillium-inc/news/equillium-participate-upcoming-investor-conferences-213500234</guid>
<pubDate>Thu, 20 Nov 2025 21:35:00 GMT</pubDate>
<description>LA JOLLA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences: Piper Sandler 37th Annual Healthcare ConferenceFormat:Fireside Chat & 1x1 MeetingsDate:Tuesday, December 2, 2025Time:11:30 AM EST Evercore ISI 8th A</description>
</item>
<item>
<title>Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update</title>
<link>https://6ix.com/company/equillium-inc/news/equillium-reports-third-quarter-2025-210500071</link>
<guid isPermaLink="true">https://6ix.com/company/equillium-inc/news/equillium-reports-third-quarter-2025-210500071</guid>
<pubDate>Thu, 13 Nov 2025 21:05:00 GMT</pubDate>
<description>Closed financing of up to $50 million; initial tranche of $30 million provides runway through 2027 Hosted key opinion leader event highlighting the important role of the Aryl Hydrocarbon Receptor (AhR) in intestinal inflammation, the unmet medical need in ulcerative colitis, and the potential clinical utility of EQ504, a novel oral AhR modulator EQ504 Phase 1 clinical study initiation planned for mid-2026 LA JOLLA, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinica</description>
</item>
<item>
<title>Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025</title>
<link>https://6ix.com/company/equillium-inc/news/equillium-host-ulcerative-colitis-kol-120000506</link>
<guid isPermaLink="true">https://6ix.com/company/equillium-inc/news/equillium-host-ulcerative-colitis-kol-120000506</guid>
<pubDate>Wed, 22 Oct 2025 12:00:00 GMT</pubDate>
<description>Virtual webinar to feature expert insights on unmet need, treatment landscape and potential clinical utility of Aryl Hydrocarbon Receptor (AhR) modulation in ulcerative colitisLA JOLLA, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced they will host a virtual key opinion leader (KOL) eve</description>
</item>
<item>
<title>Equillium Announces Leadership and Corporate Updates</title>
<link>https://6ix.com/company/equillium-inc/news/equillium-announces-leadership-corporate-updates-200200836</link>
<guid isPermaLink="true">https://6ix.com/company/equillium-inc/news/equillium-announces-leadership-corporate-updates-200200836</guid>
<pubDate>Mon, 06 Oct 2025 20:02:00 GMT</pubDate>
<description>LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced changes to its Board of Directors (BoD) and senior leadership, and other corporate updates. “The updates we announced today mark an important and timely step as we sharpen our therapeutic pipeline focus on advancing EQ504, our no</description>
</item>
<item>
<title>Equillium to Participate in the Cantor Global Healthcare Conference 2025</title>
<link>https://6ix.com/company/equillium-inc/news/equillium-participate-cantor-global-healthcare-200300290</link>
<guid isPermaLink="true">https://6ix.com/company/equillium-inc/news/equillium-participate-cantor-global-healthcare-200300290</guid>
<pubDate>Fri, 29 Aug 2025 20:03:00 GMT</pubDate>
<description>LA JOLLA, Calif., August 29, 2025--Equillium to Participate in the Cantor Global Healthcare Conference 2025</description>
</item>
<item>
<title>Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic</title>
<link>https://6ix.com/company/equillium-inc/news/equillium-announces-50-million-financing-123000161</link>
<guid isPermaLink="true">https://6ix.com/company/equillium-inc/news/equillium-announces-50-million-financing-123000161</guid>
<pubDate>Mon, 11 Aug 2025 12:30:00 GMT</pubDate>
<description>LA JOLLA, Calif., August 11, 2025--Equillium, Inc. ("Equillium" or the "Company") (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced it has entered into a definitive securities purchase agreement with leading healthcare investors that will provide up to $50 million in gross proceeds to Equillium. The private placement is comprised of (i) an initial upfront financing of approximately $30 million in gross procee</description>
</item>
<item>
<title>Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy</title>
<link>https://6ix.com/company/equillium-inc/news/equillium-announces-strategic-expansion-of-cryptocurrency-treasury-reserve-strategy</link>
<guid isPermaLink="true">https://6ix.com/company/equillium-inc/news/equillium-announces-strategic-expansion-of-cryptocurrency-treasury-reserve-strategy</guid>
<pubDate>Mon, 04 Aug 2025 04:00:00 GMT</pubDate>
<description>LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and</description>
</item>
<item>
<title>Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists</title>
<link>https://6ix.com/company/equillium-inc/news/equillium-announces-multiple-poster-presentations-120000547</link>
<guid isPermaLink="true">https://6ix.com/company/equillium-inc/news/equillium-announces-multiple-poster-presentations-120000547</guid>
<pubDate>Tue, 06 May 2025 12:00:00 GMT</pubDate>
<description>LA JOLLA, Calif., May 06, 2025--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that three posters were presented at IMMUNOLOGY2025, the annual meeting of The American Association of Immunologists taking place at the Hawaiʻi Convention Center in Honolulu, Hawaii, May 3 – 7.</description>
</item>
<item>
<title>Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504</title>
<link>https://6ix.com/company/equillium-inc/news/equillium-announces-aryl-hydrocarbon-receptor-120000639</link>
<guid isPermaLink="true">https://6ix.com/company/equillium-inc/news/equillium-announces-aryl-hydrocarbon-receptor-120000639</guid>
<pubDate>Thu, 01 May 2025 12:00:00 GMT</pubDate>
<description>LA JOLLA, Calif., May 01, 2025--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced the advancement of a novel and potent aryl hydrocarbon receptor (AhR) modulator (EQ504), which was acquired through the acquisition of Ariagen, a biotechnology company that was majority owned by Equillium’s largest investor, Decheng Capital. AhR is</description>
</item>
<item>
<title>Equillium Announces Feedback from the U.S. Food and Drug Administration</title>
<link>https://6ix.com/company/equillium-inc/news/equillium-announces-feedback-u-food-130000296</link>
<guid isPermaLink="true">https://6ix.com/company/equillium-inc/news/equillium-announces-feedback-u-food-130000296</guid>
<pubDate>Thu, 24 Apr 2025 13:00:00 GMT</pubDate>
<description>LA JOLLA, Calif., April 24, 2025--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that the company has received feedback from its Type D meeting with the U.S. Food and Drug Administration (FDA) to discuss the regulatory pathway for Accelerated Approval, as well as the company’s filing for Breakthrough Therapy designation for it</description>
</item>
<item>
<title>Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease</title>
<link>https://6ix.com/company/equillium-inc/news/equillium-announces-results-phase-3-110000303</link>
<guid isPermaLink="true">https://6ix.com/company/equillium-inc/news/equillium-announces-results-phase-3-110000303</guid>
<pubDate>Thu, 27 Mar 2025 11:00:00 GMT</pubDate>
<description>LA JOLLA, Calif., March 27, 2025--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced topline data from the Phase 3 EQUATOR study evaluating itolizumab in first-line treatment of patients with acute graft-versus-host disease (aGVHD). The study results did not demonstrate a meaningful difference in complete response (CR) or overall</description>
</item>
<item>
<title>Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights</title>
<link>https://6ix.com/company/equillium-inc/news/equillium-reports-fourth-quarter-full-110000383</link>
<guid isPermaLink="true">https://6ix.com/company/equillium-inc/news/equillium-reports-fourth-quarter-full-110000383</guid>
<pubDate>Thu, 27 Mar 2025 11:00:00 GMT</pubDate>
<description>LA JOLLA, Calif., March 27, 2025--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the fourth quarter and full year 2024, as well as corporate and clinical highlights.</description>
</item>
<item>
<title>Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis</title>
<link>https://6ix.com/company/equillium-inc/news/equillium-announces-positive-data-from-phase-2-study-evaluating-itolizumab-in-patients-with-moderate-to-severe-ulcerative-colitis</link>
<guid isPermaLink="true">https://6ix.com/company/equillium-inc/news/equillium-announces-positive-data-from-phase-2-study-evaluating-itolizumab-in-patients-with-moderate-to-severe-ulcerative-colitis</guid>
<pubDate>Thu, 06 Feb 2025 05:00:00 GMT</pubDate>
<description>Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission rate of 23.3% compared to 20.0% for adalimumab and</description>
</item>
</channel>
</rss>